Celgene Buys Juno Therapeutics: A Risky $9B Bet

Celgene has gone “all-in” on CAR-T cancer therapies, forking out $9 billion to acquire Juno Therapeutics amid much fanfare. Critics worry this wager may fail to help the biotech giant fill the gaps in its revenue stream.

Source: Forbes.com Healthcare News - January 22, 2018 Category: Pharmaceuticals Authors: Johanna Bennett, Contributor Tags: NASDAQ:CELG NASDAQ:GILD NASDAQ:JUNO Source Type: news